Global contract development and manufacturing organization (CDMO) Intravacc and biotechnology developer Primrose Bio have formalized a definitive renewal of their strategic partnership to optimize the development and supply metrics of next-generation conjugate vaccines. The foundational alliance was originally executed in March 2024. Industry analysts note that the updated commercial pact effectively creates a streamlined pathway for third-party pharmaceutical entities to access comprehensive, full-service solutions covering vaccine conjugation, manufacturing, and global supply logistics.
The underlying synchronized capabilities, underlying biological assets, and corporate partner ecosystems featured in the agreement include:
-
Technical Contributions by Intravacc: Specializing in infectious diseases, therapeutic vaccines, and advanced biologics, Intravacc infuses the renewed framework with its comprehensive technical expertise and state-of-the-art laboratory facilities. The CDMO will single-handedly spearhead operations tracking antigen conjugation process development, technical scale-up workflows, and strict Good Manufacturing Practice (GMP)-compliant production of conjugate vaccine profiles.
-
Protein Infrastructure and Primrose Bio’s Tech Platform: Primrose Bio provides ultra-pure manufacturing configurations, supply chain security, and specialized regulatory filings for its proprietary PeliCRM197 carrier protein. The biotech entity was engineered in 2023 through a structural corporate combination of the protein franchise with Primordial Genetics and Ligand Pharmaceuticals’ Pfenex Expression Technology platform. The PeliCRM197 molecule serves as a vital component in conjugate vaccine formulations and holds the distinction of being the sole CRM197 variant integrated into commercially purchasable vaccines. The biologic ingredient is distributed across diverse volume scales — ranging from milligrams to kilograms — optimized for baseline research or GMP pharmaceutical deployment.
-
Integration Into a Full-Service Solution: Ivo Lemmens, Managing Director of Intravacc, stated the enterprise is enthusiastic to renew its alignment with Primrose Bio, aiming to systematically revolutionize the conjugate vaccine landscape by linking collective internal expertise with cutting-edge partner technologies. Reaffirming the strategic outlook, Primrose Bio CEO Andrew Burch emphasized that scaling the technical capacity of the PeliCRM197 franchise alongside Intravacc successfully engineers a full-service solution, structurally filling an operational gap widely felt across the broader vaccine industry.
The reinforced operational layout guarantees seamless access to integrated conjugation and distribution pipelines for Primrose Bio’s existing tier-one pharmaceutical partners — including Merck, Jazz Pharmaceuticals, the Serum Institute of India (SII), Alvogen, Arcellx, and Arcturus — alongside alternate third-party biopharma clients.